

# Margarita Majem Tarruella

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7142800/publications.pdf>

Version: 2024-02-01

142  
papers

11,105  
citations

156536

32  
h-index

36203

101  
g-index

144  
all docs

144  
docs citations

144  
times ranked

13442  
citing authors

#	ARTICLE	IF	CITATIONS
1	Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. <i>Annals of Oncology</i> , 2022, 33, 67-79.	0.6	43
2	Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 423-433.	0.5	89
3	Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2286-2296.	3.2	14
4	PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. <i>Future Oncology</i> , 2022, 18, 903-913.	1.1	7
5	ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges. <i>Clinical Cancer Research</i> , 2022, 28, 2506-2516.	3.2	19
6	The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1 blockade agents. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1823-1835.	2.0	9
7	Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations. , 2022, 10, e004374.		13
8	SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2021). <i>Clinical and Translational Oncology</i> , 2022, 24, 712-723.	1.2	7
9	Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations. <i>European Journal of Cancer</i> , 2022, 167, 142-148.	1.3	32
10	COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3383-3393.	0.8	120
11	Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial). <i>Journal of Clinical Oncology</i> , 2022, 40, 2924-2933.	0.8	127
12	A phase II study (TACTI-002) in first-line metastatic non-small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9003-9003.	0.8	16
13	Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program. <i>Oncotarget</i> , 2022, 13, 812-827.	0.8	2
14	Efficacy and safety of capmatinib plus pembrolizumab in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9118-9118.	0.8	6
15	Multimodal prediction of response to neoadjuvant nivolumab and chemotherapy for surgically resectable stage IIIA non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8542-8542.	0.8	0
16	Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus. <i>Clinical and Translational Oncology</i> , 2021, 23, 1304-1313.	1.2	4
17	Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial. <i>Molecular Oncology</i> , 2021, 15, 43-56.	2.1	18
18	Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 93-102.	1.5	31

#	ARTICLE	IF	CITATIONS
19	Circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD(L)1 blocking agents. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1691-1704.	2.0	6
20	Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group. <i>BMC Cancer</i> , 2021, 21, 230.	1.1	9
21	Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection. <i>Lung Cancer</i> , 2021, 153, 25-34.	0.9	17
22	SEOM clinical guidelines 2020. <i>Clinical and Translational Oncology</i> , 2021, 23, 911-912.	1.2	0
23	SEOM clinical guideline for the management of cutaneous melanoma (2020). <i>Clinical and Translational Oncology</i> , 2021, 23, 948-960.	1.2	22
24	PD(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 1365.	1.0	13
25	Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM). <i>ESMO Open</i> , 2021, 6, 100048.	2.0	7
26	Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients (p): SOLID study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8531-8531.	0.8	0
27	Phase 2 study of retifanimab (INCMGA00012) in patients (pts) with selected solid tumors (POD1UM-203).. <i>Journal of Clinical Oncology</i> , 2021, 39, 2571-2571.	0.8	4
28	PD(L)1 inhibitors as monotherapy for the first-line treatment of non-small cell lung cancer patients with high PD-L1 expression: A network meta-analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9076-9076.	0.8	0
29	Imfirst: A phase IIIb, safety, single arm study of carboplatin (CB) or cisplatin (CP) plus etoposide (ET) with atezolizumab (ATZ) in patients with untreated extensive-stage small cell lung cancer (ES-SCLC) in Spain Primary safety results of the induction phase.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8567-8567.	0.8	0
30	Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors. <i>Clinical Therapeutics</i> , 2021, 43, 1092-1111.	1.1	5
31	Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. <i>European Journal of Cancer</i> , 2021, 151, 211-220.	1.3	24
32	Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. <i>Clinical and Translational Medicine</i> , 2021, 11, e491.	1.7	26
33	LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. <i>Cancer Medicine</i> , 2021, 10, 5878-5888.	1.3	11
34	Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2021, 23, 2560-2567.	1.2	7
35	Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 5878-5890.	3.2	30
36	Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. <i>Annals of Oncology</i> , 2021, 32, 1391-1399.	0.6	32

#	ARTICLE	IF	CITATIONS
37	Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. , 2021, 9, e002804.		5
38	Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. Journal of Thoracic Oncology, 2021, 16, 1547-1558.	0.5	108
39	Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1â€“Positive Advanced NSCLC. Journal of Thoracic Oncology, 2021, 16, 1718-1732.	0.5	141
40	Immunotherapy-induced isolated ACTH deficiency in cancer therapy. Endocrine-Related Cancer, 2021, 28, 783-792.	1.6	8
41	A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer. Future Oncology, 2021, 17, 4827-4835.	1.1	1
42	First-line osimertinib in patients with epidermal growth factor receptorâ€“mutant nonâ€“small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met. European Journal of Cancer, 2021, 159, 174-181.	1.3	5
43	PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain: MOREL study. Lung Cancer Management, 2021, 10, LMT53.	1.5	1
44	Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study. Translational Lung Cancer Research, 2021, 11, 0-0.	1.3	4
45	Ninetyâ€“day mortality and clinical outcomes of patients with solid tumours and COVID â€“19 infection during the first pandemic outbreak in Catalonia, Spain: A multicentre retrospective study. International Journal of Cancer, 2021, , .	2.3	0
46	Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer. Clinical and Translational Oncology, 2020, 22, 21-36.	1.2	39
47	Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses. Journal of Thoracic Oncology, 2020, 15, 274-287.	0.5	95
48	Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL). Lung Cancer, 2020, 150, 62-69.	0.9	15
49	Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study. BMC Psychology, 2020, 8, 123.	0.9	0
50	Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2020, 21, 1413-1422.	5.1	475
51	Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents. Frontiers in Oncology, 2020, 10, 1677.	1.3	32
52	Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial. British Journal of Cancer, 2020, 122, 1461-1466.	2.9	24
53	Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group. Lung Cancer, 2020, 147, 83-90.	0.9	12
54	A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial. Journal of Thoracic Oncology, 2020, 15, 1647-1656.	0.5	34

#	ARTICLE	IF	CITATIONS
55	Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1â€Positive, Advanced Nonâ€Small-Cell Lung Cancer in the KEYNOTE-010 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1580-1590.	0.8	189
56	SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019). <i>Clinical and Translational Oncology</i> , 2020, 22, 213-222.	1.2	14
57	Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving efitilagimod alpha (soluble LAG-3 protein) and pembrolizumab.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3100-3100.	0.8	14
58	Osimertinib as adjuvant therapy in patients (pts) with stage IBâ€IIIa EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.. <i>Journal of Clinical Oncology</i> , 2020, 38, LBA5-LBA5.	0.8	56
59	Leukocytes with bound platelets as a predictive biomarker for immune-related adverse events (irAEs) in advanced non-small cell lung cancer (NSCLC) patients (pts) receiving anti-PD-(L)1 agents.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15047-e15047.	0.8	0
60	Peripheral blood T-cell receptor immune repertoire characterization of resectable stage IIIa non-small cell lung cancer patients receiving neo-adjuvant chemo-immunotherapy treatment from NADIM study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9041-9041.	0.8	0
61	Patterns of disease presentation, treatment choices and survival in real world for patients diagnosed with advanced melanoma: A prospective observational study by Spanish Melanoma Group (GEM-1801).. <i>Journal of Clinical Oncology</i> , 2020, 38, e22022-e22022.	0.8	0
62	FrÃ¼he Clearance von Plasma-EGFR-Mutationen als PrÃ¤diktor fÃ¼r das Ansprechen auf Osimertinib und Vergleichs-EGFR-TKIs in der FLAURA-Studie. , 2020, 74, .		0
63	Frequenz von EGFR (epidermaler Wachstumsfaktorrezeptor)-Mutationen im Stadium IB-IIIa NSCLC nach kompletter Tumorresektion. <i>Pneumologie</i> , 2020, 74, .	0.1	0
64	790â€...A phase II study (TACTI-002) of efitilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC). , 2020, , .		3
65	Prospective Multicentric Observational Study of COVID19 in Oncohematological Patients in the Catalonia Region: The Opposite Effect of Steroids on Survival. <i>Blood</i> , 2020, 136, 34-35.	0.6	0
66	Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions. <i>Molecular Oncology</i> , 2019, 13, 2633-2645.	2.1	69
67	Durvalumab plus platinumâ€etoposide versus platinumâ€etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. <i>Lancet</i> , The, 2019, 394, 1929-1939.	6.3	1,274
68	Differences in coping strategies among young adults and the elderly with cancer. <i>Psychogeriatrics</i> , 2019, 19, 426-434.	0.6	29
69	Prognostic effect of VEGF gene variants in metastatic non-small-cell lung cancer patients. <i>Angiogenesis</i> , 2019, 22, 433-440.	3.7	28
70	Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program. <i>Clinical and Translational Oncology</i> , 2019, 21, 1270-1279.	1.2	38
71	SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 3-17.	1.2	110
72	SEOM clinical guidelines on nutrition in cancer patients (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 87-93.	1.2	66

#	ARTICLE	IF	CITATIONS
73	Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. <i>Annals of Oncology</i> , 2019, 30, 281-289.	0.6	88
74	Risk of malnutrition and emotional distress as factors affecting health-related quality of life in patients with resected cancer. <i>Clinical and Translational Oncology</i> , 2019, 21, 687-691.	1.2	13
75	Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2019, 21, 556-571.	1.2	29
76	Lung cancer in Spanish women: The WORLD07 project. <i>European Journal of Cancer Care</i> , 2019, 28, e12941.	0.7	6
77	Manejo cl�nico de los eventos adversos cut�neos en pacientes tratados con quimioterapia: consenso nacional de la Academia Espa�ola de Dermatolog�a y Venereolog�a y de la Sociedad Espa�ola de Oncolog�a M�dica. <i>Actas Dermo-sifilograficas</i> , 2019, 110, 448-459.	0.2	8
78	Neoadjuvant chemo-immunotherapy for the treatment of stage IIIA resectable non-small-cell lung cancer (NSCLC): A phase II multicenter exploratory study�Final data of patients who underwent surgical assessment.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8509-8509.	0.8	44
79	Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9020-9020.	0.8	39
80	Haematological biomarkers of pathological response on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20026-e20026.	0.8	0
81	Tracking plasma KRAS mutations (mu) in lung adenocarcinoma (LUAC) patients (p) and branching evolution.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9055-9055.	0.8	0
82	Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy. <i>Melanoma Research</i> , 2018, 28, 195-203.	0.6	17
83	BRAF inhibitors in metastatic non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 589-592.	0.6	27
84	Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. <i>BMC Cancer</i> , 2018, 18, 106.	1.1	9
85	Correlation between immune-related adverse events (irAEs) and efficacy in patients with solid tumors treated with immune-checkpoints inhibitors (ICIs).. <i>Journal of Clinical Oncology</i> , 2018, 36, 3064-3064.	0.8	24
86	Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study�NADIM study-SLCC.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8521-8521.	0.8	41
87	NORA trial (GCEP 15/02): First efficacy results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 8537-8537.	0.8	1
88	Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A randomized phase 2 study (GOAL, Spanish Lung Cancer Group).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9012-9012.	0.8	7
89	Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy. <i>Clinical and Translational Oncology</i> , 2017, 19, 219-226.	1.2	3
90	KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2017, 19, 884-890.	1.2	11

#	ARTICLE	IF	CITATIONS
91	Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 435-444.	5.2	172
92	A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib. <i>Lung Cancer</i> , 2017, 108, 154-160.	0.9	18
93	Lung Cancer in Never-Smoking Women: A Sub-Analysis of the Spanish Female-Specific Database WORLD07. <i>Cancer Investigation</i> , 2017, 35, 358-365.	0.6	9
94	Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions. <i>Annals of Oncology</i> , 2017, 28, 2248-2255.	0.6	95
95	Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database. <i>Clinical and Translational Oncology</i> , 2017, 19, 1537-1542.	1.2	4
96	Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease. <i>Clinical Lung Cancer</i> , 2017, 18, 68-76.e2.	1.1	59
97	A consensus statement on the gender perspective in lung cancer. <i>Clinical and Translational Oncology</i> , 2017, 19, 527-535.	1.2	26
98	Small-cell lung cancer in the era of immunotherapy. <i>Translational Lung Cancer Research</i> , 2017, 6, S67-S70.	1.3	5
99	Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis. <i>Translational Lung Cancer Research</i> , 2017, 6, S21-S34.	1.3	9
100	Factors associated with better overall survival (OS) in patients with previously treated, PD-L1-expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010. <i>Journal of Clinical Oncology</i> , 2017, 35, 9090-9090.	0.8	14
101	SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016). <i>Clinical and Translational Oncology</i> , 2016, 18, 1237-1242.	1.2	10
102	Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer. <i>BMC Cancer</i> , 2016, 16, 312.	1.1	21
103	Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , 2016, 17, 1643-1652.	5.1	533
104	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. <i>Lancet</i> , 2016, 387, 1540-1550.	6.3	5,456
105	miRNA-197 and miRNA-184 are associated with brain metastasis in EGFR-mutant lung cancers. <i>Clinical and Translational Oncology</i> , 2016, 18, 153-159.	1.2	24
106	Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC. <i>Journal of Clinical Oncology</i> , 2016, 34, 3030-3030.	0.8	4
107	Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1-Positive NSCLC. <i>Journal of Clinical Oncology</i> , 2016, 34, 9015-9015.	0.8	10
108	Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010. <i>Journal of Clinical Oncology</i> , 2016, 34, 9024-9024.	0.8	7

#	ARTICLE	IF	CITATIONS
109	BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. <i>Scientific Reports</i> , 2015, 5, 17499.	1.6	55
110	Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study. <i>Cancer Epidemiology</i> , 2015, 39, 291-297.	0.8	39
111	BIM and SHP2 expression levels to predict clinical outcome to EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p).. <i>Journal of Clinical Oncology</i> , 2015, 33, e19078-e19078.	0.8	0
112	Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 4647-4659.	3.2	130
113	Lung cancer in women: an overview with special focus on Spanish women. <i>Clinical and Translational Oncology</i> , 2014, 16, 517-528.	1.2	22
114	Beyond EGFR TKI in EGFR-mutant Non-Small Cell Lung Cancer patients: Main challenges still to be overcome. <i>Cancer Treatment Reviews</i> , 2014, 40, 723-729.	3.4	19
115	Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. <i>Cancer Letters</i> , 2014, 353, 160-166.	3.2	76
116	Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. <i>Lung Cancer</i> , 2014, 84, 161-167.	0.9	81
117	Phase IB study to evaluate efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients (P) with epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC) (NCT=1513174/GECP-GOAL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8079-8079.	0.8	4
118	Observational retrospective study to describe the management of advanced epidermal growth factor receptor (EGFR) mutated (M+) non-small cell lung cancer (NSCLC) patients (pts) in Spain (NCT01795352).. <i>Journal of Clinical Oncology</i> , 2014, 32, e19133-e19133.	0.8	2
119	Open, phase II randomized trial of gefitinib alone versus olaparib (AZD2281) plus gefitinib in advanced non-small cell lung cancer (NSCLC) patients (P) with epidermal growth factor receptor (EGFR) mutations: Spanish Lung Cancer Group trial (NCT=1513174/GECP-GOAL).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS8127-TPS8127.	0.8	3
120	Effect of BIM and mTOR expression on clinical outcome to erlotinib in EGFR-mutant non-small cell lung cancer (NSCLC) patients (p).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8072-8072.	0.8	0
121	The FAM-GEM-1 study: Frequency and characteristics of familial melanoma in Spain.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9039-9039.	0.8	0
122	An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents. <i>Clinical and Translational Oncology</i> , 2013, 15, 343-357.	1.2	33
123	Phase IB study of olaparib (AZD2281) plus gefitinib in EGFR-mutant patients (p) with advanced non-small-cell lung cancer (NSCLC) (NCT01513174/GECP-GOAL).. <i>Journal of Clinical Oncology</i> , 2013, 31, 2581-2581.	0.8	3
124	Interim analysis of the Spanish Lung Cancer Group (SLCG) BRCA1-RAP80 Expression Customization (BREC) randomized phase III trial of customized therapy in advanced non-small cell lung cancer (NSCLC) patients (p) (NCT00617656/GECP-BREC).. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA8002-LBA8002.	0.8	2
125	Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2013, 2, 226-37.	1.3	35
126	EGFR mutation heterogeneity and mixed response to EGFR tyrosine kinase inhibitors of non small cell lung cancer: a clue to overcoming resistance. <i>Translational Lung Cancer Research</i> , 2013, 2, 445-8.	1.3	22



#	ARTICLE	IF	CITATIONS
127	Nondisruptive mutations of TP53 and overall survival (OS) in advanced non-small-cell lung cancer (NSCLC) patients (p).. Journal of Clinical Oncology, 2013, 31, 11029-11029.	0.8	0
128	ROR1 mRNA expression in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) with the T790M mutation: A potential therapeutic target.. Journal of Clinical Oncology, 2013, 31, 11027-11027.	0.8	0
129	The predictive role of integrated BRCA1 and HERC2 mRNA expression in advanced non-small cell lung cancer (NSCLC) patients (p) treated with platinum-based first-line chemotherapy.. Journal of Clinical Oncology, 2013, 31, 11078-11078.	0.8	0
130	Integrated genomic analysis of EGFR-mutant non-small cell lung cancer immediately following erlotinib initiation in patients.. Journal of Clinical Oncology, 2013, 31, 11067-11067.	0.8	0
131	Interim analysis of The Spanish Lung Cancer Group (SLCG) BRCA1-RAP80 Expression Customization (BREC) randomized phase III trial of customized therapy in advanced non-small-cell lung cancer (NSCLC) patients (p) (NCT00617656/GECP-BREC). Journal of Clinical Oncology, 2013, 31, LBA8002-LBA8002.	0.8	1
132	Never-smoking women with lung cancer from the Spanish WORLD07 database.. Journal of Clinical Oncology, 2012, 30, 1531-1531.	0.8	1
133	EGFR compound mutants and survival on erlotinib in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study.. Journal of Clinical Oncology, 2012, 30, 7522-7522.	0.8	17
134	Skin toxicity associated with outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations in the EURTAC study.. Journal of Clinical Oncology, 2012, 30, 7542-7542.	0.8	2
135	Population survey to assess the knowledge of smoking habit and its consequences on women (w) in Spain.. Journal of Clinical Oncology, 2012, 30, e12000-e12000.	0.8	1
136	Menstrual status and lung cancer in female patients from the Spanish WORLD07 database.. Journal of Clinical Oncology, 2012, 30, e12012-e12012.	0.8	3
137	DNA repair components modulating the function of breast cancer susceptibility gene 1 (BRCA1) in advanced non-small cell lung cancer (NSCLC) patients (p) treated with platinum-based chemotherapy.. Journal of Clinical Oncology, 2012, 30, e18130-e18130.	0.8	0
138	Effect of germline polymorphisms of DNA repair genes on chemotherapy outcome in advanced non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology, 2012, 30, e18057-e18057.	0.8	0
139	MCPH1 (BRIT1) and outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) harboring EGFR mutations.. Journal of Clinical Oncology, 2012, 30, e18131-e18131.	0.8	1
140	Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists. Supportive Care in Cancer, 2011, 19, 1983-1990.	1.0	40
141	Incidence of chemotherapy-induced nausea and vomiting after highly and moderately emetogenic chemotherapy in the era of NK-1 receptor antagonists. Perception versus reality. Journal of Clinical Oncology, 2009, 27, e20636-e20636.	0.8	0
142	Multicenter prospective trial of customized erlotinib for advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Final results of the Spanish Lung Cancer Group (SLCG) trial. Journal of Clinical Oncology, 2009, 27, 8023-8023.	0.8	11